Cargando…

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients

The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NAC). We retrospectively analyzed the clinical data of 294 patients with stage II/III breast cancer to evaluate the clinical sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yang, Zhang, Jing, Chen, Hui, Zhou, Ying, Hong, Liping, Ma, Yue, Chen, Nannan, Zhao, Weipeng, Tong, Zhongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852345/ https://www.ncbi.nlm.nih.gov/pubmed/36684294 http://dx.doi.org/10.3389/fsurg.2022.1037215

Ejemplares similares

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules
por: He, Lihong, et al.
Publicado: (2022)

Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
por: Jin, Xi, et al.
Publicado: (2015)

Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study
por: Xiang, Meijuan, et al.
Publicado: (2022)

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
por: Zhao, Weipeng, et al.
Publicado: (2021)

The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
por: Liu, Jinzhao, et al.
Publicado: (2022)

Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer
por: Zhao, Weipeng, et al.
Publicado: (2021)

Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer
por: Yang, Gaohua, et al.
Publicado: (2022)

Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation
por: Zhang, Chi, et al.
Publicado: (2023)

Prognostic Value of the Distribution of Lymph Node Metastasis in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
por: Chen, Bin, et al.
Publicado: (2021)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
por: Lan, Ailin, et al.
Publicado: (2022)

Immediate Breast Reconstruction After Neoadjuvant Chemotherapy: Factors Associated With Surgical Selection and Complications
por: Chi, Weiru, et al.
Publicado: (2023)

Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: A., Ashok, et al.
Publicado: (2022)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
por: Shi, Zhendong, et al.
Publicado: (2023)

Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Liu, Ziyi, et al.
Publicado: (2021)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study
por: Li, Yijun, et al.
Publicado: (2022)

Prognostic value of preoperative chemotherapy for thymic epithelial tumors: A propensity-matched analysis based on the SEER database
por: Fan, Yan, et al.
Publicado: (2023)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The predictive value of prognostic nutritional index on early complications after robot-assisted radical cystectomy
por: Wang, Yiduo, et al.
Publicado: (2022)

Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma Using Image-Guided Clip Placement
por: Pandurangappa, Vikas, et al.
Publicado: (2023)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

The Prognostic Significance of the Fibrinogen-to-Albumin Ratio in Patients With Triple-Negative Breast Cancer: A Retrospective Study
por: Yang, Qinheng, et al.
Publicado: (2022)

Prognostic significance of Naples prognostic score in operable renal cell carcinoma
por: Wang, Yaohui, et al.
Publicado: (2022)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial
por: Li, Ziyu, et al.
Publicado: (2018)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Higher Pathological Complete Response Rate of Less than 10 Total Axillary Lymph Nodes After Axillary Lymph Node Dissection Following Neoadjuvant Chemotherapy in Breast Cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022)

Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy
por: Hu, Bing, et al.
Publicado: (2023)

Prognostic Significance of Signet-Ring Cell Components in Patients With Gastric Carcinoma of Different Stages
por: Dong, Xiaoyuan, et al.
Publicado: (2021)

Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
por: Yu, Deguo, et al.
Publicado: (2022)

Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis
por: Zhai, Yuhao, et al.
Publicado: (2023)

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients
por: Wang, Ruo-Xi, et al.
Publicado: (2018)

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
por: Pierga, J-Y, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_o6lof42oid8gjkhl2of0ah6mi1